Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 217-222 , October 2010

DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio

  • John Thoms, MD, MSc

      Affiliations

    • Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    • Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Robert G. Bristow, MD, PhD

      Affiliations

    • Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    • Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    • Prostate Cancer Research Program, Campbell Family Cancer Research Institute, Ontario Cancer Institute, Toronto, Ontario, Canada
    • Corresponding Author InformationAddress reprint requests to Robert G. Bristow, MD, PhD, Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue Toronto, ON M5G 2M9, Canada

References 

  1. Bristow RG, Ozcelik H, Jalali F, et al. Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiother Oncol. 2007;83:220–230
  2. Begg AC. Predicting response to radiotherapy: Evolutions and revolutions. Int J Radiat Biol. 2009;85:825–836
  3. Bentzen SM. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6:702–713
  4. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25:4096–4103
  5. Bentzen SM. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol. 2008;18:75–88
  6. Chan N, Koch CJ, Bristow RG. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med. 2009;9:401–410
  7. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–447
  8. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues. Cancer. 2005;104:891–905
  9. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents (part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome). Semin Radiat Oncol. 2006;16:51–58
  10. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204
  11. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–3790
  12. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006;12:2545–2554
  13. West CM, Elliott RM, Burnet NG. The genomics revolution and radiotherapy. Clin Oncol R Coll Radiol. 2007;19:470–480
  14. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19:238–245
  15. Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: Sensor, signaler and therapeutic target. Clin Oncol R Coll Radiol. 2004;16:29–39
  16. Loser DA, Shibata A, Shibata AK, et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther. 2010;9:1775–1787
  17. Neijenhuis S, Verwijs-Janssen M, Kasten-Pisula U, et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst). 2009;8:336–346
  18. Helleday T. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst). 2007;6:923–935
  19. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  20. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  21. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134
  22. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol. 2008;8:363–369
  23. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17:235–248
  24. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1:315–322
  25. Sourisseau T, Maniotis D, McCarthy A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med. 2010;2:130–142
  26. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest. 2007;117:1440–1449
  27. Das AK, Chen BP, Story MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007;67:5267–5274
  28. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate. 2009;69:1091–1100
  29. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008;7:993–999
  30. Supiot S, Zhao H, Wiman K, et al. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol. 2008;86:407–411
  31. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115
  32. Bhogal N, Jalali F, Bristow RG. Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol. 2009;85:732–746
  33. Bristow RG, Hill RP. Hypoxia and metabolism (Hypoxia, DNA repair and genetic instability). Nat Rev Cancer. 2008;8:180–192
  34. Sprong D, Janssen HL, Vens C, et al. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys. 2006;64:562–572
  35. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins and therapeutic resistance. Cancer Res. 2008;68:605–614
  36. Hegan DC, Lu Y, Stachelek GC, et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and Rad51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A. 2010;107:2201–2206
  37. Rainey MD, Charlton ME, Stanton RV, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008;68:7466–7474
  38. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13:3033–3042

 Supported by operating grants from Prostate Cancer Canada, the Terry Fox Research Institute, the Ontario Institute for Cancer Research, the US Army DOD Prostate Program, an infrastructure grant from the Canadian Foundation for Innovation grant to the STTARR Innovation Facility, and in part by the Ontario Ministry of Health and Long-Term Care.

 The views expressed do not necessarily reflect those of the OMOHLTC. RGB is a Canadian Cancer Society Research scientist and JT is a CFCRI-OCI Prostate Cancer Fellow.

PII: S1053-4296(10)00045-7

doi: 10.1016/j.semradonc.2010.06.003

Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 217-222 , October 2010

Article Tools

* Image Usage & Resolution